Chronic kidney disease, heart failure and neprilysin inhibition by Haynes, R, Zhu, D, Judge, P, Herrington, W, Kalra, P, Baigent, C

Revascularization versus medical therapy for renal-artery stenosis. by Wheatley, K, Ives, N, Gray, R, Kalra, P, Moss, J, Baigent, C, Carr, S, Chalmers, N, Eadington, D, Hamilton, G, Lipkin, G, Nicholson, A, Scoble, J

Effects of sacubitril/valsartan versus irbesartan in patients with chronic kidney disease: a randomised double-blind trial by Haynes, R, Judge, P, Staplin, N, Herrington, W, Storey, B, Bethel, A, Bowman, L, Brunskill, N, Cockwell, P, Hill, M, Kalra, P, McMurray, J, Taal, M, Wheeler, D, Landray, M, Baigent, C, UK HARP-III Collaborative Group

Controlling intramolecular interactions in the design of selective, high-affinity, ligands for the CREBBP Bromodomain by Brand, M, Clayton, J, Moroglu, M, Schiedel, M, Picaud, S, Buck, J, Skwarska, A, Bolland, H, Chan, A, Laurin, C, Scorah, A, See, L, Rooney, T, Andrews, K, Fedorov, O, Perell, G, Kalra, P, Vinh, K, Cortopassi, W, Heitel, P, Christensen, K, Cooper, R, Paton, R, Pomerantz, W, Biggin, P, Hammond, E, Filippakopoulos, P, Conway, S